Entering text into the input field will update the search result below

ATyr Pharma on deck for IPO

May 01, 2015 12:45 PM ETaTyr Pharma, Inc. (LIFE) StockLIFEBy: Douglas W. House, SA News Editor1 Comment
  • San Diego-CA-based aTyr Pharma (NASDAQ:LIFE) is set for its IPO of 5.36M shares of common stock at $13 - 15.
  • The clinical stage firm develops medicines for rare diseases. Its technology is based on Physiocrine biology, a newly discovered class of naturally occurring physiological modulators. The company has identified ~300 to date. The company believes they promote homeostasis, a fundamental process of restoring stressed or diseased tissue to a healthier state.
  • Its lead product candidate is the Phase 1b/2-stage Resolaris, for the potential treatment of adult patients with facioscapulohumeral muscular dystrophy (FSHD), a severe and rare genetic disorder characterized by muscle weakness and wasting. The muscles most affected are those on the face (facio), around the shoulder blades (scapulo-) and in the upper arms (humeral). The FDA designated Resolaris an Orphan Drug for FSHD in February.
  • 2014 Financials ($M): Operating Expenses: 23.6 (+21.0%); Net Loss: (24.8) (-14.3%); Cash Burn: (22.8) (-31.8%).

Recommended For You

About LIFE Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
LIFE--
aTyr Pharma, Inc.